GEA Farmaceutisk Fabrik A/S, a subsidiary of Bristol Myers Squibb Co., is a company headquartered in Copenhagen, Denmark. The firm makes generic pharmaceuticals. Bristol Myers Squibb Co. acquired GEA Farmaceutisk Fabrik An on September 05, 1995.

Grünenthal GmbH engages in the research and development of pharmaceutical products. It specializes in pain, gout, and inflammation. The company was founded by Hermann Wirtz in 1946 and is headquartered in Aachen, Germany.

Intervet International BV engages in the manufacture and marketing of animal health products. It offers vaccines, anti-infectives, anti-parasitics, feed additives and products for fertility management. The firm products are used for treatment and care of poultry, pigs, cattle, sheep, goats, horses, fish, shrimp and companion animals. The company was founded by Wim Hendrix in 1949 and is headquartered in Boxmeer, the Netherlands.

Qingdao Vland Biotech Co., Ltd. engages in R&D, production and sales of enzyme preparations, probiotics and animal health products. It mainly specializes in the research and development of four main product categories which are enzymes, probiotics, vaccines and animal health products. It provides solutions to an industries including agriculture, animal husbandry, textile, paper making, household cleaning and detergents, food, biofuel and environmental protection. The company was founded on February 23, 2005 and is headquartered in Qingdao, China.

Imperial Innovations is a technology commercialization and venture capital investor that focuses on technology. Imperial Innovations no longer invests in startups and now functions as the technology-transfer office of Imperial College. Imperial Innovations is focused on commercialising leading UK academic research sourced from the 'golden triangle' formed between Cambridge, Oxford and London. We are a technology commercialisation company that combines the activities of technology transfer, intellectual property protection and licensing, company incubation and investment. Innovations is focused on commercialising the most promising UK academic research across a broad range of technology sectors, and has developed particular expertise in: therapeutics, medtech, engineering and materials and information communication technology.

Heze Puen Pharmaceutical Co., Ltd., established on 2004-09-23, Business scope includes powder,Powder,Premix,oral solution,disinfectant(liquid,solid)Production and sales of granules(Only for the production and operation of veterinary drugs,The validity period is subject to the license);Production and sales of additive premixed feed(The validity period is subject to the license);vitamins(II)vitaminsCproduction and sales of(The validity period is subject to the license),liquid disinfectant(Free of Hazardous Chemicals)(The validity period is subject to the license).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Oxford University Innovation is the University of Oxford's technology transfer company and manages the University's intellectual property portfolio, working with University researchers on identifying, protecting and marketing technologies through licensing, spin-out company formation and material sales. Oxford University Innovation also manages Oxford University Consulting, which arranges consulting services providing clients access to the expertise of the University's academics. Oxford University’s overarching Strategic Plan begins, “The University of Oxford aims to lead the world in research and education” immediately followed by, “They seek to do this in ways which benefit society on a national and a global scale.” Oxford University Innovation helps staff and students to apply their expertise and research for wider social and economic benefit. Their role is to help University staff and students bring the benefits of their research and expertise to create impact in wider society. They support Oxford’s researchers, staff and students, offering commercial skills and a range of specialist resources in order to maximise research impact. Income is shared with those involved according to the University’s Regulations.

Interway International Ltd. is a private company headquartered in Hong Kong, Hong Kong, that manufactures and distributes chemicals. Sufan Siauw is the current CEO of the firm.

Danyang Heng'an Chemical Technology Research Institute Co., Ltd., established on 2009-06-30, Business scope includes medicinal chemistry,Product development and technology transfer of materials chemistry,Chemical Products(except dangerous goods)Sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) licensed items:Import and export;Technology Import and Export(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results)

Elder Pharmaceuticals Ltd. manufactures and sells pharmaceuticals bulk drugs and formulations. It deals with pharmaceuticals and related products, which manufactures and markets prescription pharmaceutical brands, surgical and medical devices. The company was founded by Jagdish Kantiswarup Saxena on April 2, 1983 and is headquartered in Mumbai, India.

Part of Beijing Wanger Biotechnology Co. Ltd., Beijing Kwinbon Biotechnology Co., Ltd. is a company headquartered in Changping District, China, that operates as testing laboratory specialized in research and development of rapid detection instrument and immunodiagnostic reagents for food safety.

Intas is among the top-10 Indian pharmaceutical companies and the largest privately held pharmaceutical company in India, with annual turnover in excess of US$ 1 billion, of which 60% comes from international operations. The group has an extensive geographic footprint with presence in 70 countries worldwide and more than 80% of export revenue coming from US, UK and EU. Intas operates over 10 manufacturing facilities worldwide. These facilities have regulatory approvals from multiple global agencies and enjoy an excellent reputation for quality and compliance. The group has capabilities to produce a wide variety of dosage forms including solid orals, liquids, lyophilized sterile preparations, creams, drops and injectables. Intas employs 12,000 people globally with over 400 located in Europe. The company employs over 800 scientists; spends approximately 6% of sales on R&D per annum and has been granted 27 international patents. In addition to generics formulation, R&D is focused on value added products such as biosimilars, value added and improved generics using novel drug delivery systems (NDDS) and innovative active pharmaceutical ingredients (API). Intas has the largest commercialised portfolio of biosimilars in India and is the first Indian pharmaceutical company to launch a biosimilar in the EU. Intas is privately held, based in Ahmedabad India, and backed by two leading financial investors, Temasek and ChrysCapital

Shenyang Sanjiu Pharmaceutical Co., Ltd., established on 2009-02-17, Business scope includes sterile raw materials,API,Powder injection production(The specific production scope is subject to the drug production license),Research and development of pharmaceutical intermediates,Production,Sales;Self-operated and agent import and export of various commodities and technologies,Except for the goods and technologies that the state restricts the company to operate or prohibits the import and export of;General cargo transportation(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

infirst HEALTHCARE is a new consumer healthcare company focused on improving well established drugs with IP protected solutions for the OTC/Primary care markets which can be launched within 12-36 months. infirst is a spin-out from SEEK, a UK privately-owned drug discovery group which uses its intellectual property to create breakthrough medicines addressing major diseases, bringing radical improvements to human health. infirst is led by CEO, Manfred Scheske, who was previously President of GSK's US$3 billion European Consumer Healthcare business (including brands such as alli, Aquafresh, Beechams, Corsodyl, Lucozade, Niquitin, Panadol. Piriton, Poligrip, Ribena, Sensodyne, Solpadeine, Zantac and Zovirax) from 2004 to 2010 and also spent six years as President of GSK's Consumer Healthcare business in North America

Pharnext is an advanced clinical-stage biopharmaceutical company founded in April 2007 by renowned scientists and entrepreneurs including Professor Daniel Cohen and collaborators, pioneers in modern genomics. The company develops new therapeutics for neurodegenerative diseases - orphan and common – where there are currently no cures and existing therapies available. Pharnext is the pioneer of a new paradigm for the discovery of medicinal drugs: PLEOTHERAPY™. The R&D approach protected by Pharnext systemizes new uses of approved drugs. It is based on network pharmacology utilizing complex and extensive genomic data to identify the thousands of molecules possibly involved in a disease. From this disease molecular network, Pharnext deduces synergistic combinations of drugs already approved but for unrelated indications. These novel therapeutics called PLEODRUG™ are then developed at new optimal doses and under new formulations. They offer several key advantages: efficacy, safety, and intellectual property including several composition of matter patents already granted. The proof of concept of the PLEOTHERAPY approach was obtained with PLEODRUG PXT3003 in Charcot-Marie-Tooth disease type 1A (CMT1A) through positive and consistent Phase 2 and Phase 3 results. PLEODRUG PXT864 generated encouraging Phase 2 data in Alzheimer’s disease. They also plan to develop the same agent in other orphan and common neurodegenerative diseases such as Parkinson’s disease and amyotrophic lateral sclerosis (ALS).

Pfizer Ltd. is a biopharmaceutical company that develops and provides medicines, vaccines, and consumer healthcare products. Its products include prescription and counterfeit medicines, and over-the-counter products. The company was founded in 1952 and is headquartered in Tadworth, the United Kingdom.

Shandong Zhefen Scientific Instrument Co., Ltd., established on 2020-11-18, Business scope includes general items:Instrument sales;Experimental analysis instrument sales;Glass fiber and product sales;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Instrument Manufacturing;Manufacturing of experimental analysis instruments;Manufacturing of Drug Testing Instruments;Glassware Sales;Specialty Chemicals Sales(Free of Hazardous Chemicals);Drug testing equipment sales(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Zhengzhou Bairui Animal Pharmaceutical Co., Ltd., established on 2005-11-18, The business scope includes powder injection,powder/Premix,Powder(Contains Chinese herbal extracts),tablet/Granules(Contains Chinese herbal extracts),Terminally Sterilized Bulk Non-intravenous Injectables(Contains Chinese herbal extracts),Terminally sterilized small volume injection(Contains Chinese herbal extracts)/oral solution(Contains Chinese herbal extracts),terminally sterilized uterine injection/Terminally Sterilized Breast Implants,disinfectant(liquid);Detergent production and sales;Disinfectant production and sales;additive premixed feed(Operating with a valid operating license)production and sales of;Sanitation Pesticide Sales;Sales of spray disinfection equipment;Production and sales of feed ingredients;Pharmaceutical preparation technical consultation,Technical Services;Import and export of goods or technology.

Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.